Tag Archives: BPMC
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (NASDAQ: BPMC) and X4 Pharmaceuticals (NASDAQ: XFOR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Blueprint Medicines (BPMC – Research Report) and X4 Pharmaceuticals (XFOR – Research Report) with bullish sentiments. Blueprint Medicines (BPMC) In a report
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (NASDAQ: BPMC) and Neurocrine (NASDAQ: NBIX)
Analysts fell to the sidelines weighing in on Blueprint Medicines (BPMC – Research Report) and Neurocrine (NBIX – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Blueprint Medicines (BPMC) In a
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (NASDAQ: BPMC), Verrica Pharmaceuticals (NASDAQ: VRCA) and Inmune Bio (NASDAQ: INMB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Blueprint Medicines (BPMC – Research Report), Verrica Pharmaceuticals (VRCA – Research Report) and Inmune Bio (INMB – Research Report) with bullish sentiments.
H.C. Wainwright Reiterates a Buy Rating on Blueprint Medicines (BPMC)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $66.00. The company’s shares closed last Wednesday at $58.97. According to TipRanks.com, Fein is a 5-star analyst
Blueprint Medicines (BPMC) Receives a Buy from Morgan Stanley
Morgan Stanley analyst David Lebovitz maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $88.00. The company’s shares closed last Thursday at $58.65. According to TipRanks.com, Lebovitz is a 3-star analyst
Cowen & Co. Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Blueprint Medicines (BPMC – Research Report). The company’s shares closed last Monday at $57.96. According to TipRanks.com, Frahm is a 1-star analyst with an
